Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of HIPEC with Nanoliposomal Irinotecan
NCT04088786Phase 1Completed
- Sponsor
- Stony Brook University
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan in primary peritoneal cancer (PPC), pseudomyxoma peritonei (PMP), mucinous adenocarcinoma (MAC) and 4 more, sponsored by Stony Brook University. Primary endpoint: Number of participants with treatment-related adverse events at 4 weeks. Started Oct 2019; status: completed.
02
Drugs
irinotecan
03
Conditions
primary peritoneal cancer (PPC)pseudomyxoma peritonei (PMP)mucinous adenocarcinoma (MAC)colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04088786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088786.